$CEMI. Chembio Diagnostics.

Received an extension to gain NASDAQ compliance until April 3, 2023.

"Short it for pennies. Buy it for dollars. "

Currently trading under cash on hand and at 30% of book value.

Company received a $3.25M contract from the C.D.C. to develop a rapid test for Syphilis.

Last July it traded over 600,000,000 shares in two days and the share price tripled when the company announced a $23.5M order from Brazil for its dual Covid/flu test.

Chembio has the only F.D.A. approved dual HIV-SYPHILIS test. The H.I.V. test market is over $4,000,000,000. News of a large order is overdue and when announced could triple the share price.

Chembio is the ideal takeover candidate by a "big pharma" drug company that wants to diversify into testing or expand its current testing capabilities.

C.F.O. Larry Steenvoorden is well connected in the industry. He has the perfect background to negotiate a buyout at 5X? Potential suitors are $DGX, $AZN, $TAK and $JNJ. Chembio has worked with each of them on developing diagnostic tests.

Buy/cover before the next p.r. announcing a new order or the best case scenario that the company is in takeover talks or announcing the company is being acquired.